Form D
View Original Filing
Notice of Exempt Offering of Securities
Item 1. Issuer's Identity
Name of Issuer:
SOMAXON PHARMACEUTICALS, INC.
Jurisdiction of Incorporation/Organization
DE
Year of Incorporation/Organization
Over Five Years Ago
Item 2 Issuer Principal Place of Business and Contact Information
420 STEVENS AVENUE
SUITE 210
SOLANA BEACH, CA 92075
Phone Number:
subscription required
Item 3. Related Persons
Name
RICHARD W. PASCOE
Address
subscription required
Relationship(s)
- EXECUTIVE OFFICER
- DIRECTOR
Clarification of Response
Item 3. Related Persons
Name
DAVID F. HALE
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
TERRELL A. COBB
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
MICHAEL L. EAGLE
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
KURT VON EMSTER
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
ERLE T. MAST
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
JESSE I. TREU
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
KURT C. WHEELER
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
THOMAS G. WIGGANS
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
JEFFREY W. RASER
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
BRIAN T. DORSEY
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
MATTHEW W. ONAITIS
Address
subscription required
Relationship(s)
Clarification of Response
Item 4. Industry Group
PHARMACEUTICALS
Item 5. Issuer Size
Revenue Range (for issuer not specifying "hedge" or "other investment" fund in Item 4 above)
DECLINE TO DISCLOSE
Item 6. Federal Exemptions and Exclusions Claimed
Item 7. Type of Filing
New Notice
Date of First Sale in this Offering:
07/08/2009
Item 8. Duration of Offering
Does the issuer intend this offering to last more than one year?
No
Item 9. Type(s) of Securities Offered
- Equity
- Option, Warrant or Other Right to Acquire Another Security
- Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security
Item 10. Business Combination Transaction
Is this offering being made in connection with a business combination
transaction, such as a merger, acquisition or exchange offer?
No
Clarification of Response
Item 11. Minimum Investment
Minimum Investment accepted from any outside investor
0
Item 13. Offering and Sales Amounts
Total Offering Amount
5999990
Total Amount Sold
5999990
Total Remaining to be Sold
0
Clarification of Response
Item 14. Investors
Securities in the offering have been or may be sold to persons
who do not qualify as accredited investors,
Number of non-accredited investors who already have invested in the offering:
Total number of investors who already have invested in the offering:
16
Item 15. Sales Commissions and Finders' Fees Expenses
Sales Commissions:
0.0
Finders' Fees
0.0
Clarification of Response
Item 16. Use of Proceeds
Provide the amount of the gross proceeds of the offering
that has been or is proposed to be used for payments to any of the persons required
to be named as executive officers,directors or promoters in response to Item 3 above.
0.0
Clarification of Response
Signature and Submission
Issuer Name
SOMAXON PHARMACEUTICALS, INC.
Issuer Signature
/S/ MATTHEW W. ONAITIS
Signer Name
MATTHEW W. ONAITIS
Signer Title
VICE PRESIDENT, GENERAL COUNSEL AND SECRETARY
Signature Date
07/14/2009